Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors
PRESENTED TO: BioPharma Services Inc.
PRESENTED BY: N. RAYAD, N. GHARAVI, J. HE, F. TRABELSI
Opportunities and Challenges in Clinical Studies of Generic Anticancer Tyrosine Kinase Inhibitors – Tyrosine kinase inhibitors (TKIs) are multi-targeted anticancer drugs with high activity towards several families of receptor and nonreceptor tyrosine kinases involved in angiogenesis, tumor growth and metastatic progression of cancer.
Many of these will be running off-patent, sequentially, in the next few years. Bioequivalence (BE) studies are needed for the development and regulatory approval of generic products of TKIs.
Biopharma Services Inc. (BPSI) has a proven track record and experience with BE studies on TKIs and other oncology drug products.
To access the entire publication and view the full resolution PDF, please complete the form.